Adaptimmune’s debt financing deal; Tenaya to cut workers

Plus, news about Brixton Biosciences, Merck KGaA, Medincell, CellProthera and GSK:

Adaptimmune inks up to $125M debt financing: The biotech gets $25 million to start as it prepares for a commercial launch of its cell therapy. The money came through shortly after Genentech axed a collaboration that could’ve delivered $3 billion to Adaptimmune. — Kyle LaHucik

Tenaya lays off 22% of its staff: The biotech will reduce its workforce to save money for its gene therapies that are in the clinic for certain forms of cardiomyopathy. It had 140 full-time employees at the end of 2023, according to its most recently disclosed tally. — Kyle LaHucik

Brixton Biosciences raises $33M: The Series B is set to support clinical testing of a drug-free injectable. The startup, a Massachusetts General Brigham spinout, seeks…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks